Mechanisms underlying the blood pressure‐lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial

AIM: To study the effects of the sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor empagliflozin, the angiotensin receptor blocker (ARB) losartan, and their combination on blood pressure, while studying the mechanisms potentially involved. METHODS: A total of 24 people with type 2 diabetes (T2D) (ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Scholtes, Rosalie A., Mosterd, Charlotte M., Hesp, Anne C., Smits, Mark M., Heerspink, Hiddo J. L., van Raalte, Daniël H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087931/
https://www.ncbi.nlm.nih.gov/pubmed/36089810
http://dx.doi.org/10.1111/dom.14864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087931/
https://www.ncbi.nlm.nih.gov/pubmed/36089810
http://dx.doi.org/10.1111/dom.14864

Ejemplares similares